Strategic focus
Oncology medicines
Oral and liquid opportunities assessed with specialist formulation, evidence, demand, storage and regulatory dependencies.
Strategic pharmaceutical portfolio
A portfolio of questions before it becomes a portfolio of products.
NovaPharm evaluates selected pharmaceutical categories through product-specific rights, source, regulatory, quality and commercial evidence. This is not an ecommerce or availability catalogue.
Current priorities
Category direction with product-level discipline.
Opportunity assessment
Specialty medicines
Hard-to-source and clinically important categories considered through qualified B2B and regulatory pathways.
Partner sought
Oral liquid formulations
Technically differentiated formulations requiring appropriate development, manufacturing and stability evidence.
Regulatory preparation
Selected licensed generics
Established categories assessed for compliant sourcing, documentation and commercial viability.
Strategic review
Cardiovascular, respiratory and metabolic categories
Selected opportunities considered product by product; no availability is implied.
Qualified enquiry
Hospital and hard-to-source products
B2B opportunities reviewed without implying stock, authorisation or NHS supply.
Assessment sequence
Every opportunity earns its place.
- 01Strategic fit
- 02Rights and source
- 03Regulatory route
- 04Quality evidence
- 05Commercial viability